Home » Stocks » Rocket Pharmaceuticals

Rocket Pharmaceuticals, Inc. (RCKT)

Stock Price: $26.46 USD 0.02 (0.08%)
Updated Aug 7, 2020 4:00 PM EDT - Market closed
After-hours: $27.00 +0.54 (2.04%) Aug 7, 7:37 PM

Stock Price Chart

Key Info

Market Cap 1.46B
Revenue (ttm) n/a
Net Income (ttm) -88.84M
Shares Out 55.19M
EPS (ttm) -1.68
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 7, 2020
Last Price $26.46
Previous Close $26.44
Change ($) 0.02
Change (%) 0.08%
Day's Open 26.50
Day's Range 26.12 - 27.73
Day's Volume 238,808
52-Week Range 9.01 - 27.73

More Stats

Market Cap 1.46B
Enterprise Value 1.28B
Earnings Date (est) Nov 5, 2020
Ex-Dividend Date n/a
Shares Outstanding 55.19M
Float 32.40M
EPS (basic) -1.67
EPS (diluted) -1.68
FCF / Share -1.83
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 8.83M
Short Ratio 15.12
Short % of Float 26.30%
Beta 1.65
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 4.87
Revenue n/a
Operating Income -86.49M
Net Income -88.84M
Free Cash Flow -101.04M
Net Cash 183.51M
Net Cash / Share 3.33
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -16.34%
ROE -34.50%
ROIC -42.10%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (11)

Buy 11
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$36.33*
(37.30% upside)
Low
31.0
Current: $26.46
High
47.0
Target: 36.33
*Average 12-month price target from 9 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year20192018201720162015201420132012
Revenue--------
Operating Income-76.15-71.16-19.77-7.57-20.40-7.70-6.65-5.85
Net Income-77.27-74.52-19.58-7.57-67.98-9.53-7.62-6.06
Shares Outstanding49.0139.386.806.834.580.260.250.25
Earnings Per Share-1.58-1.89-2.88-1.11-14.88-54.08-40.20-32.16
Operating Cash Flow-64.66-53.79-15.96-5.50-17.42-9.74-6.46-6.94
Capital Expenditures-23.27-1.43-0.76-0.34-0.41---
Free Cash Flow-87.93-55.22-16.72-5.84-17.83-9.74-6.46-6.93
Cash & Equivalents30620818.351261113.6212.791.37
Total Debt47.4541.45-48.96-7.156.812.71
Net Cash / Debt25916618.3577.51111-3.545.99-1.34
Assets37225120.151301135.5212.861.42
Liabilities64.8257.284.6356.484.5110.2810.533.79
Book Value30719415.5273.17109-51.56-38.90-30.93
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Rocket Pharmaceuticals, Inc.
Country United States
Employees 72
CEO Gaurav Shah

Stock Information

Ticker Symbol RCKT
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: RCKT

Description

Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating pediatric diseases. It has clinical-stage lentiviral vector (LVV) programs under clinical testing to treat fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction, and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. It also has additional infantile malignant osteopetrosis, a genetic disorder characterized by increased bone density and bone mass secondary to impaired bone resorption. In addition, the company has an adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure. It has license agreements with Fred Hutchinson Cancer Research Center; Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; CIEMAT and UCL Business PLC; The Regents of the University of California; and REGENXBIO Inc. The company also has a research and collaboration agreement with Lund University; and strategic collaboration agreement with Stanford University School of Medicine. Rocket Pharmaceuticals, Inc. is headquartered in New York, New York.